XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
$ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2022
Aug. 31, 2020
Mar. 31, 2020
Aug. 31, 2018
Mar. 31, 2022
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Dec. 31, 2018
Dec. 31, 2021
Dec. 31, 2020
Other Commitments [Line Items]                      
Gain (loss) on strategic investment         $ 339 $ 145          
Research and development         128,855 56,973          
Restricted cash         5,770 $ 5,770       $ 5,770 $ 5,770
Letter of Credit | Corporate Credit Card Program                      
Other Commitments [Line Items]                      
Restricted cash         2,000            
Letter of Credit | Fleet Program                      
Other Commitments [Line Items]                      
Restricted cash         400            
Cersci Therapeutics                      
Other Commitments [Line Items]                      
Upfront consideration and transaction costs   $ 52,800                  
Upfront payment   $ 44,300                  
Upfront payment conditions   The Company incurred an aggregate of $52.8 million in upfront consideration and transaction costs, of which, $44.3 million was paid through the issuance of approximately 1.2 million shares of the Company’s common stock.                  
Cersci Therapeutics | Research And Development Expense Member                      
Other Commitments [Line Items]                      
Assets acquisition and upfront payment             $ 45,700        
Stoke Therapeutics, Inc. [Member]                      
Other Commitments [Line Items]                      
Upfront payment $ 60,000                    
Mile stone payments payable $ 907,500                    
License Agreements | Neuren | North America                      
Other Commitments [Line Items]                      
Upfront payment     $ 10,000                
Upfront license fee       $ 10,000              
License Agreements | Neuren | Research And Development Expense Member | North America                      
Other Commitments [Line Items]                      
Upfront payment               $ 10,000 $ 10,000    
Maximum                      
Other Commitments [Line Items]                      
Mile stone payments payable         $ 3,100,000            
Maximum | Cersci Therapeutics                      
Other Commitments [Line Items]                      
Common stock issuance   1.2                  
Maximum | Cersci Therapeutics | Development Commercialization and Sales Milestones                      
Other Commitments [Line Items]                      
Compensation expense related to mergers to former holders   $ 887,000                  
Maximum | License Agreements | Neuren | North America                      
Other Commitments [Line Items]                      
Mile stone payments payable     $ 515,000 $ 455,000       $ 515,000